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Abstract
Ribosomal S6 Kinase 2 (RSK2) is a member of the p90RSK family of serine/threonine kinases, which are widely expressed and
respond to many growth factors, peptide hormones, and neurotransmitters. Loss-of function mutations in the RPS6KA3
gene, which encodes the RSK2 protein, have been implicated in Coffin-Lowry Syndrome (CLS), an X-linked mental
retardation disorder associated with cognitive deficits and behavioral impairments. However, the cellular and molecular
mechanisms underlying this neurological disorder are not known. Recent evidence suggests that defective DNA damage
signaling might be associated with neurological disorders, but the role of RSK2 in the DNA damage pathway remains to be
elucidated. Here, we show that Adriamycin-induced DNA damage leads to the phosphorylation of RSK2 at Ser227 and
Thr577 in the chromatin fraction, promotes RSK2 nuclear translocation, and enhances RSK2 and Atm interactions in the
nuclear fraction. Furthermore, using RSK2 knockout mouse fibroblasts and RSK2-deficient cells from CLS patients, we
demonstrate that ablation of RSK2 impairs the phosphorylation of Atm at Ser1981 and the phosphorylation of p53 at Ser18
(mouse) or Ser15 (human) in response to genotoxic stress. We also show that RSK2 affects p53-mediated downstream
cellular events in response to DNA damage, that RSK2 knockout relieves cell cycle arrest at the G2/M phase, and that an
increased number of cH2AX foci, which are associated with defects in DNA repair, are present in RSK2-deficient cells. Taken
together, our findings demonstrated that RSK2 plays an important role in the DNA damage pathway that maintains
genomic stability by mediating cell cycle progression and DNA repair.
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Introduction
Coffin-Lowry syndrome (CLS) is an X-linked mental retarda-
tion disorder caused by mutations in the Rps6ka3 gene, which
encodes ribosomal S6 kinase (RSK) 2 [1]. This syndrome is
characterized by psychomotor, growth, and cognitive retardation,
as well as facial, hand, and skeletal anomalies [2].
CLS patients have markedly reduced cerebellar and hippocam-
pal volumes compared to healthy controls [3]. RSK2 plays a key
role in this neurological disorder. In the adult mouse brain, RSK2
is highly expressed in regions with high synaptic activity, including
the cerebellar Purkinje cells and the pyramidal cells of the CA3
hippocampal region [4]. Studies have shown that the functional
impairment of neurotransmission and plasticity due to AMPAR
dysfunction may contribute to the cognitive deficit observed in
RSK2 knockout (KO) mice [5]. In addition, loss of RSK2 function
decreases neurogenesis during cerebral cortex development [6].
These data suggest that RSK2 plays an important role in learning
and memory in both humans and mice and that RSK2 deficiency
might lead to cognitive and behavioral dysfunction.
Several lines of evidence have linked DNA damage and repair
systems to neurological disorders. DNA damage can be caused by
exogenous or endogenous factors, such as ionizing radiation (IR),
chemotherapeutic drugs, and stalled replication forks [7]. Upon
exposure to DNA-damage reagents, mammalian cells trigger a
sequence of multi-component biochemical reactions to maintain
genome integrity. At the core of the signaling network are PI3
kinase-like kinases (PIKKs), including Atm, Atr and DNA-PKcs
[8]. Atm and Atr are recruited to nuclear foci by the MRN
(Mre11-Rad50-NBS) complex [9], where they phosphorylate
proteins such as p53, Chk1, Chk2, and H2AX to activate cell
cycle checkpoints and/or induce apoptosis [10].
Patients with Ataxia Telangiectasia (A-T) and Seckel Syndrome-
1 (SCKL1) exhibit severe cerebellar degeneration, microcephaly
and mental retardation, which result from deficiencies in Atm and
Atr, respectively [11–12]. Furthermore, growing evidence links
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DNA damage to cognitive impairment in experimental animals
and patients receiving genotoxic chemotherapeutic drugs [13–14].
For instance, data from a longitudinal study of breast cancer
patients who were evaluated using structural and functional
Magnetic Resonance Imaging (MRI) before treatment and 1 and
12 months after treatment suggest a pattern of reduced activation
in frontal areas during a working memory task [15]. Recently,
RSK2 was reported to directly phosphorylate histone H2AX. The
incorporation of phosphorylated H2AX in chromatin is an
indicator of DNA damage, suggests a possible role for RSK2 in
maintaining chromatin stability [16]. In addition, RSK2 activates
p53 in vitro and in vivo, and co-localizes with p53 in the nucleus
[17]. However, the primary function of RSK2 in the DNA
damage pathway remains unclear.
While investigating the role of RSK2 in the DNA damage
response and DNA repair, we observed the phosphorylation of
RSK2 at Ser227 and Thr577 in response to Adriamycin-induced
DNA damage. We demonstrated that RSK2 activates the Atm/
p53-dependent DNA damage pathway and that RSK2 also
interacted and co-localized with Atm in the nucleus upon DNA
damage. RSK2 participated in the DNA damage response by
affecting p53-controlled cell cycle progression and DNA repair
mechanisms. The absence of RSK2 relieved cell cycle arrest at the
G2/M phase, increasing the number of cH2AX foci (which are
associated with DNA repair) in both RSK2 knockout (KO) mouse
embryonic fibroblasts (MEFs) and CLS patient fibroblast cells.
Hence, our study has uncovered a novel role for RSK2 in the
DNA damage pathway and provided a link between CLS, a
neurological disorder caused by mutated RSK2, and defects in the
DNA damage response.
Results
Genotoxic stress results in RSK2 phosphorylation at
Ser227 and Thr577
To maintain genomic integrity, DNA damage in mammalian
cells rapidly activates a number of specific signaling pathways
that initiate cell cycle arrest and subsequent DNA repair. To
examine the potential role of RSK2 in the DNA damage
response, we treated low-passage, non-immortalized MEFs with
DNA-damaging agents for various lengths of time, and then, we
detected the phosphorylation of RSK2 in response to the DNA
damage. DNA damage was initially induced by treatment with
Adriamycin (AD), a chemotherapeutic agent used to treat a wide
variety of cancers. AD is a topoisomerase II inhibitor that has
been shown to induce DSBs and SSBs by activating both Atm
and Atr [18]. We found that after 2 hr of AD treatment, RSK2
was phosphorylated at Ser227 (,1.6-fold) in the N-terminal
kinase domain (NTKD) and Thr577 (,1.6-fold) in the C-
terminal kinase domain (CTKD). RSK2 remained phosphory-
lated for up to 16 hr after AD treatment (Fig. 1A and B). The
levels of RSK2 expression remained constant during the AD
treatment.
Several DNA damage response and DNA repair proteins, such
as DNA-PK, Rad51, and HMGB1, associate with chromatin in
response to DNA damage [19–20]. To test whether RSK2
associates with chromatin after DNA damage, we treated MEFs
with 0.5 mM of AD and then isolated the chromatin-associated
proteins [21]. We found an increased amount of RSK2
phosphorylated at Ser227 and Thr577 in the chromatin fraction
after treating with AD for 2 hr (Fig. 1C and D), but this effect was
not observed in the cytosolic fraction (Fig. 1E and F). This
indicates that activated RSK2 associates with chromatin in
response to DNA damage.
RSK2 deficiency impairs the Atm/p53-dependent DNA
damage pathway
Our data show that RSK2 is phosphorylated at Ser227 and
Thr557 in response to genotoxic stress, which is known to cause
DSBs and SSBs. To determine the role of RSK2 in the DNA
damage response, we first examined whether the absence of
functional RSK2 would affect the activation of the Atm/p53-
dependent DNA damage pathway, which is known to trigger the
DNA damage signaling network [10]. We cultured RSK2 wild
type (WT) and knockout (KO) MEFs and treated the cells with
0.5 mM AD for 2 hr, 8 hr, or 16 hr. We found that AD-induced
DNA damage induced the phosphorylation of RSK2 at both
Ser227 and Thr577 (Fig. 2A). Next, we assessed the activation of
Atm in RSK2 WT and KO MEFs treated with AD. We observed
phosphorylation of Atm at Ser1981 in RSK2 WT MEFs starting
at 2 hr after AD treatment, indicating the presence of DNA DSBs.
However, the phosphorylation of Atm at Ser1981 was reduced in
RSK2-deficient MEFs compared to the WT cells (Fig. 2A).
p53 is one of the most important effector molecules downstream
of Atm in the DNA damage response. p53 phosphorylation
induced by DNA damage either stabilizes p53 or enhances its
transactivation ability. We therefore investigated the phosphory-
lation of p53 in both RSK2 WT and KO MEFs. Western blot
analysis revealed that p53 was phosphorylated at Ser18 (human
Ser15) in WT cells. RSK2 deficiency led to drastically reduced
phosphorylation at Ser18, as well as a reduction in p53 up-
regulation in response to AD (Fig. 2A). p53 is a master gene that
regulates cell cycle progression, apoptosis, and DNA repair in cells
with DNA damage. Decreased phosphorylation of p53 at Ser18
indicates that downstream target genes that control these cellular
events might be affected. Indeed, we found that while AD
treatment of WT cells leads to an induction of p21, a potent cyclin-
dependent kinase inhibitor (CDKI) that functions as a regulator of
cell cycle progression at the G1 phase [22], this effect was
abolished in RSK2 KO cells (Fig. 2A). We further observed that
RSK2 deficiency had no effect on the expression levels of Bax, a
molecule that is involved in p53-mediated apoptosis [23],
compared to WT cells, suggesting that RSK2 plays a critical role
in DNA damage-induced p53 activation and cell cycle progres-
sion. To further confirm the effects of the RSK2-mediated DNA
damage response, we overexpressed RSK2 in RSK2-deficient
MEFs and observed that the disrupted phosphorylation of Atm at
Ser1981 and p53 at Ser18 in these cells was rescued by RSK2
overexpression (Fig. 2B).
To further confirm this finding, we analyzed CLS fibroblasts
obtained from patients with RSK2 mutations. Genotoxic stress-
induced RSK2 phosphorylation at Ser227 and Thr577 was
observed in healthy human fibroblasts (Fig. 2C). Notably,
however, we observed a decreased phosphorylation of Atm at
Ser1981 in CLS fibroblasts (Fig. 2C). Furthermore, p53 phos-
phorylation at Ser15 was abolished in the RSK2-deficient CLS
cells, as well as downstream p21 signaling. However, Bax activity
was not affected. Taken together, our findings from the RSK2 KO
mouse cell line and the RSK2-deficient human cell line indicate
that RSK2 activates the Atm/p53-dependent DNA damage
pathway.
Genotoxic stress promotes RSK2 interaction with Atm
To further define the mechanism of how RSK2 activates the
Atm-dependent DNA damage pathway, we next sought to
determine whether RSK2 and Atm interact with each other
under conditions of genotoxic stress. RSK2 shuttles between the
cytoplasm and the nucleus upon activation [24]. Co-immunopre-
cipitation assays showed that upon overexpression of RSK2 and
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Atm in NIH cells, Atm associates with RSK2. Importantly, this
interaction was further enhanced by genotoxic stress induced by
AD treatment for 2 hr (Fig. 3A). To confirm this result, we co-
transfected RSK2 and Atm into MEFs, which were then
immunostained for both proteins. Under normal conditions,
RSK2 is predominantly in the cytoplasmic compartment, whereas
Atm is mainly nuclear. Thus, there was little co-localization
between these two proteins (Fig. 3B). However, after AD
administration for 2 hr, enhanced nuclear co-localization of
RSK2 and Atm was observed (Fig. 3B). These results suggest that
Atm interacts with RSK2 under conditions of genotoxic stress.
RSK2 deficiency relieves genotoxic stress-induced G2/M
cell cycle arrest
DNA damage typically results in three cellular responses: cell
cycle arrest, increased DNA repair, and apoptosis [25]. Previous
studies have shown that RSK2 is mainly involved in proliferation
and survival upon exposure to UVB or an AD analogue [17,26].
In addition, our results also suggested that in response to DNA
damage, RSK2 primarily affects p21, which is involved in cell
cycle regulation rather than apoptosis (Fig. 2). Hence, we
examined the impact of RSK2 deficiency on cell cycle arrest
under genotoxic stress conditions for 8 hr and 24 hr. We
performed flow cytometry analysis of AD-treated RSK2 KO
and WT MEFs. Propidium Iodide (PI) staining showed approx-
imately 40% of control (untreated) cells were in G2/M phase
(Fig. 4A, 4B, 4D). Treatment of cells with AD increased this
number to 80%, indicating AD-induced G2/M arrest (Fig. 4D).
Interestingly, reduced percentage of cells in the G2/M phase
(58%) was observed in the RSK2 KO cells (Fig. 4D). Moreover,
recovered number of cells in the G1/S phase was detected in the
RSK2 KO cells (Fig. 4C). These data indicate that RSK2
Figure 1. Genotoxic stress results in RSK2 phosphorylation at Ser227 and Thr577. A. MEFs were treated with 0.5 mM Adriamycin (AD) for
specific periods of time to induce DNA lesions. Protein levels of total RSK2 and RSK2 phosphorylated at Ser227 and Thr577 were analyzed by western
blot. B. Quantitation of RSK2 phosphorylation at Ser227 and Thr577. The value of phospho-RSK2 at time zero in the absence of AD was set at 1.0.
Increased levels of phospho-RSK2 were observed 2 hr after exposure of the MEFs to AD. C. RSK2 is associated with chromatin and activated by a DNA
damaging reagent. MEFs were treated with 0.5 mM AD for various time points, followed by fractionation into the cytosolic and chromatin
compartments. Western blot was performed to analyze the protein levels of total RSK2 and phospho-RSK2. D. Quantitation of RSK2 phosphorylation
at Ser227 and Thr577 in the chromatin fraction. The value of phospho-RSK2 at time zero in the absence of AD was set at 1.0. An increased level of
phosphorylated RSK2 was observed in the chromatin fraction, indicating an increased association between activated RSK2 and chromatin under
genotoxic stress, whereas the level of cytosolic phospho-RSK2 remained the same as shown in E and F. For each experiment, at least three replicates
were performed, and similar results were obtained. Representative results from one experiment are shown. All data are shown as the mean plus or
minus the standard deviation of the mean (mean6 SD). A significant difference was defined as *P,0.05, **P,0.01, and ***P,0.001 compared to the
control.
doi:10.1371/journal.pone.0074334.g001
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Figure 2. RSK2 activates the Atm/p53-dependent DNA damage
pathway under genotoxic stress. A. RSK2 activates the Atm/p53-
dependent DNA damage pathway under genotoxic stress in MEFs. RSK2
WT and KO MEFs were isolated from E14.5 mouse embryos. Cells were
treated with 0.5 mM AD for 2 hr, 8 hr, or 16 hr. The cell lysates were
then analyzed by western blot against Atm, phospho-Atm(Ser1981),
and DNA damage response target genes downstream of p53, including
phospho-p53(Ser18), Bax and p21. The RSK2 KO MEFs shows very little
activation signal due to the RSK2 deficiency, and this leads to decreased
phosphorylation of Atm at Ser1981, decreased p53 protein stability and
transactivation, and decreased levels of p21 expression. Total RSK2 and
b-actin were used as internal controls to confirm the RSK2 knockout
and equal protein loading. B. Overexpression of RSK2 in the RSK2 KO
MEFs rescued Atm and p53 activation. RSK2 WT and KO MEFs were
isolated from E14.5 mouse embryos. RSK2 was overexpressed in RSK2
KO MEFs, and a control plasmid was overexpressed in the WT and KO
RSK2 cells. Cells were treated with 0.5 mM AD for 2 hr, 8 hr or 16 hr. The
cell lysates were then analyzed by western blot for the expression of
Atm, phospho-Atm(Ser1981), p53 downstream targets, and phospho-
p53 (Ser18). C. RSK2 activates the Atm/p53-dependent DNA damage
pathway under genotoxic stress in human fibroblasts. Healthy
fibroblasts (GM09621) and RSK2-deficient fibroblasts from CLS patients
(GM03321) were cultured and exposed to 0.5 mM AD for various times.
Western blot analysis was conducted using phospho-specific antibodies
for Atm and p53. Total RSK2 and b-actin were used as internal controls
to confirm RSK2 knockout and equal protein loading.
doi:10.1371/journal.pone.0074334.g002
Figure 3. Genotoxic stress promotes the interaction of RSK2
with Atm. A. Ectopically expressed RSK2 interact with Atm, and the
formation of this complex is enhanced under conditions of genotoxic
stress. NIH cells were transfected with the indicated expression
constructs and treated with 0.5 mM AD 2 hr or left untreated. Atm
was then immunoprecipitated from the cell lysates. The immunopre-
cipitated proteins and their associated proteins were detected by
western blot analysis using anti-Atm, -RSK2 antibodies, respectively. B.
Under conditions of genotoxic stress, activated RSK2 translocated to the
nucleus and co-localized with Atm. MEF cells were co-transfected with
Atm and RSK2 and then treated with 0.5 mM AD for 2 hr. The cells were
fixed, permeabilized, and blocked, and immunocytochemistry was
performed using primary antibodies against RSK2 and Atm and FITC-
conjugated or Alexa Fluor 555 Donkey anti-mouse IgG (H+L) secondary
antibodies. Scale bars: 5 mm. A representative Z-stack image shows
RSK2 and Atm double-positive cells.
doi:10.1371/journal.pone.0074334.g003
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deficiency relieves AD-induced G2/M arrest, suggesting that
RSK2 plays a critical role in genotoxic stress-induced cell cycle
progression.
RSK2 deficiency increases vulnerability of the cells to
genotoxic stress
As impaired DNA repair would lead to cell apoptosis, we also
test the cell viability in RSK2 WT and KO cells treated with
Adriamycin (0.5 mM). As shown in Fig. 5A, Adriamycin treatment
significantly decreased cell viability in RSK2 KO cells but not in
RSK2 WT cells. Compared with RSK2 WT cells, RSK2 KO cells
displayed lower cell viability at each time point after treatment. In
addition to that, we also performed TUNEL assay to detect the
cell death effect under the genotoxic stress. RSK2 KO cells
exhibited more cell death than RSK2 WT cells after 24 h
Adriamycin treatment (Fig. 5B, C). Our results suggested that
RSK2 deficiency increased vulnerability of cells to genotoxic
stress.
RSK2 deficiency results in an increased number of cH2AX
foci in response to genotoxic stress
When the cell cycle is arrested, specific DNA repair mechanisms
are activated depending on the types of DNA lesions and the cell
cycle phase [27]. We next examined the potential role of RSK2 in
DNA repair under genotoxic stress conditions. Proteins that are
responsible for the DNA damage response and DNA repair are
rapidly recruited to the sites of breaks, leading to the formation of
nuclear foci. These foci disappear upon completion of DNA
damage repair [28]. We therefore investigated whether the AD-
induced formation of cH2AX foci is affected by RSK2. cH2AX is
phosphorylated at Ser139 by various kinases and forms foci at the
sites of DSBs [29–31]. Due to this localization pattern, cH2AX
foci are commonly used to quantify the severity of DSBs and the
efficiency of DNA repair, with a high number of foci indicating a
deficiency in DNA repair. We treated RSK2 WT and KO MEFs
with AD for different periods of time (from 2 hr to 48 hr) and
quantified the average number of cH2AX foci per cell by
immunostaining the cells for endogenous cH2AX (Fig. 6A).
Untreated WT and KO MEFs formed very few foci (,1–2 foci/
cell). After 2 hr of treatment with 0.5 mMAD, RSK2 WT and KO
MEFs started to form foci, but no difference was detected between
the two groups (Fig. 6A and 6B). We observed an increase in the
number of foci per cell in both RSK2 WT and KO MEFs over
time, which reached a peak at 24 hr (Fig. 6B: WT-75 foci/cell,
and KO-84 foci/cell). Interestingly, we observed an increase in the
number of foci per cell at 8 hr (61 foci/cell), 24 hr (84 foci/cell),
and 48 hr (75 foci/cell) in the RSK2 KO group compared to the
WT cells (which showed 55 foci/cell, 75 foci/cell, and 48 foci/cell
at these time points, respectively) (Fig. 6A and B). The significant
difference in the number of cH2AX foci observed over time (from
8 to 48 hr) suggests that RSK2 deficiency might cause a delay in
DNA repair, resulting in the persistently high number of cH2AX
foci in RSK2-deficient MEFs.
To determine whether DNA repair efficiency is impaired in
CLS, we treated healthy human fibroblasts and CLS patient
fibroblasts with AD and measured the number of cH2AX foci per
cell. We observed an increase in cH2AX foci formation for both
groups beginning at 2 hr of AD treatment, which reached a peak
at 8 hr, followed by a reduction in the number of foci number by
16 hr. However, CLS fibroblasts displayed a significantly higher
number of foci per cell at 2 hr (18 foci/cell), 8 hr (48 foci/cell),
and 16 hr (21 foci/cell) of AD treatment, compared to healthy
fibroblasts (which showed 13 foci/cell, 32 foci/cell, and 16 foci/
Figure 4. RSK2 regulates cell cycle progression in response to
genotoxic stress. A and B. Cell cycle profile analysis using FACs. RSK2
WT (A) and KO (B) MEFs were treated with 0.5 mM AD at various time
points, and the cells were fixed and stained with propidium iodide,
followed by flow cytometry analysis. C. At 24 hr, an increased
percentage of RSK2 KO MEFs had entered the G1/S phase compared
to WT MEFs. D. At 24 hr, a decreased number of RSK2 KO MEFs had
entered the G2/M phase compared to WT MEFs. For each experiment, at
least three independent replicates were performed, and similar results
were obtained. Representative results from one experiment are shown.
All data were shown as the mean plus or minus the standard deviation
of the mean (mean 6 SD). A significant difference was defined as
***P,0.001 compared to WT cells.
doi:10.1371/journal.pone.0074334.g004
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cell at these time points, respectively) (Fig. 6C). Hence, the results
from human RSK2 mutant cell lines were consistent with our
findings in RSK2-deficient mouse cells (Fig. 6A and 6B), indicating
that the lack of functional RSK2 leads to deficiency in DNA
repair.
We next analyzed TopBP1, a nuclear protein that localizes at
the sites of DNA DSBs and affects DNA repair [32–33]. Notably,
western blot analysis demonstrated that the levels of TopBP1
decreased in RSK2 KO MEFs in response to AD treatment,
compared to WT cells (Fig. 6D). TopBP1 was also down-regulated
in the CLS patient fibroblast cells (Fig. 6 E). Thus, the decreased
level of TopBP1 in RSK2-deficient cells indicates that RSK2 is
important in maintaining DNA repair efficiency.
Discussion
Increasing evidence suggests that RSK2 is involved in DNA
damage-induced signaling pathways. For instance, RSK2 is
activated by UV irradiation, which causes DNA strand breaks,
and this activation transduces signals to specific downstream
effectors, such as RNA-activated Protein Kinase (PKR) and Bcl-2-
Associated Death promoter (BAD) [34–35]. However, the
physiological function of RSK2 in the DNA damage response
and DNA repair has not been well elucidated. Here, we show that
RSK2 is phosphorylated at both Ser227 and Thr577 in response
to genotoxic stress. We also show that RSK2 activates the Atm/
p53-dependent DNA damage pathway by interacting with Atm,
which acts as a sensor for DNA damage. We further showed that
RSK2 KO relieves AD-induced cell cycle arrest at the G2/M
check point and subsequently inhibits the DNA repair process by
reducing the formation of cH2AX foci (Fig. 7).
Our results suggested that RSK2 was activated under genotoxic
stress. As shown in Fig. 1, in MEF cells treated with adriamycin,
the phosphorylation of RSK2 was elevated and accumulated in
nuclear. It has been reported that RSKs were activated via ERK
and JNK pathway under UV-irritation [26,36], which suggested a
possible signaling mechanism for RSK2 activation in cells with
genotoxic stress. Further investigation will be carried out to
elucidate the underlying mechanisms.
RSK2 does not contain a classic nuclear localization signal
(NLS), and the mechanism by which it translocates to the nucleus
has not been investigated previously. In response to mitogen
treatment, RSK2 is slowly released from stress granules and
shuttles rapidly in and out of the nucleus [37]. Several studies have
suggested that the phosphorylation status of RSK is important for
its nuclear translocation [38]. Other studies have also indicated
that various binding partners regulate the subcellular distribution
of RSK [39–40]. ATM is the key player in DNA damage response,
which is predominantly present within the nucleus of cultured
human cells, with a small fraction present in the cytoplasm [41].
Our results demonstrated that RSK2 deficiency impaired ATM
function under genotoxic stress. As suggested in Fig. 2, RSK2 KO
Figure 5. RSK2 deficiency increases cell vulnerability to genotoxic stress. A. WST1 assay indicated the cell viability decreases in RSK2 WT
and KO MEFs treated with AD (0.5 mM) at indicated time scale (0–24 h). n$8. ***P,0.001 compared to WT cells at same time point. ###P,0.001
compared to 0 h control. B. TUNEL assay indicated the percentage of dead cells after 24 h AD (0.5 mM) treatment. Representative image of TUNEL
assay for cell death in RSK2 WT and KO MEFs treated with AD. Scale bar indicated 50 mm. C. Grouped result showing the statistics of TUNEL assay in
RSK2 WT and KO MEFs n$5. ***P,0.001 compared to WT cells.
doi:10.1371/journal.pone.0074334.g005
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cells and CLS Fibroblast with RSK2 mutants displayed a
dysfunction of ATM activation. Overexpression of RSK2 was
able to rescue the ATM phosphorylation levels but not ATM
protein levels (Fig. 2B), indicating that RSK2 might be essential for
ATM activation. Moreover, we found that cytosolic RSK2
translocates to the nucleus when DNA damage occurs. As Atm
is predominantly expressed in the nucleus, transport of RSK2 to
the nucleus enables the formation of a RSK2-Atm complex,
promotes the activation of ATM and facilitates the Atm/p53-
dependent DNA damage pathway in response to DNA damage.
Atm, Atr, and DNA-PKs are DNA damage-sensing protein
kinases that signal the presence of DNA lesions, initiate cell cycle
arrest, and DNA repair or apoptosis through a series of
phosphorylation events [27].
We postulate that the phosphorylation of RSK2 is required to
fully activate Atm at Ser1981 and p53 at Ser18 (mouse) or Ser15
Figure 6. RSK2 regulates DNA repair efficiency under conditions of genotoxic stress. A. Increased formation of AD-induced cH2AX foci in
RSK2 KO MEFs. RSK2 KO and WT MEFs were exposed to 0.5 mM AD for different periods of time from 2 hr to 48 hr, and then immunostained for
endogenous cH2AX. Scale bars: 10 mm. B. Quantitation of the data from image (A) showing the number of cH2AX foci per cell in RSK2 WT and KO
MEFs. RSK2 KO cells showed a significant increase in the number of cH2AX foci at 8 hr, 24 hr, and 48 hr, compared to WT cells. C. Similar to RSK2 KO
cells, RSK2-deficient fibroblasts from CLS patients displayed an increased number of cH2AX foci compared to fibroblasts from healthy controls at 2 hr,
8 hr, and 16 hr. D. RSK2 KO MEFs show decreased expression levels of TopBP1, compared to WT MEFs. RSK2 WT and KO MEFs were treated with
0.5 mM AD treatment for 2 hr, 8 hr, and 16 hr, follow by western blot analysis with an antibody against TopBP1. The expression level of TopBP1 in
RSK2 WT MEFs increased in response to 0.5 mM AD treatment, but this response was impaired in RSK2 KO MEFs. E. Similarly, TopBP1 was down-
regulated in response to AD in the CLS patient fibroblast cells compared to cells healthy control. For each experiment, at least three independent
replicates were performed, and similar results were obtained. Representative results from one experiment are shown. All data are shown as the mean
plus or minus the standard deviation of the mean (mean6 SD). A significant difference was defined as *P,0.05, **P,0.01, and ***P,0.001 compared
to WT cells.
doi:10.1371/journal.pone.0074334.g006
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(human) in response to genotoxic stress. Atm has long been known
to phosphorylate p53 at Ser15, promoting p53 accumulation and
activation in response to DNA damage [42]. Previous studies have
indicated that p53 is another important substrate of RSK2 for
chromatin remodeling and regulation of gene expression. RSK2
activates and phosphorylates p53 (Ser15) in vitro and in vivo and co-
localizes with p53 in the nucleus [17]. Upon UVB stimulation,
phosphorylation of p53 at Ser15 in cells from CLS patients lacking
RSK2 was noticeably reduced compared to p53 phosphorylation
in healthy cells, showing a crucial role for RSK2 in p53 activation
in response to DNA damage. As p53 is a common target for both
Atm and RSK2 in the presence of DNA lesions, this suggests the
existence of a DNA damage pathway that involves both RSK2
and Atm. In addition, our analysis also showed that RSK2
interacts with Atm shortly after the induction of DNA damage,
while Atm activation is greatly diminished when RSK2 is absent
or mutated (Fig. 2). Quantification of cH2AX foci revealed that
DNA repair ability is reduced in Atm-defective human fibroblasts
treated with Neocarzinostatin, a radiomimetic reagent that
induces DSBs [43]. This observation correlates well with our
observation that RSK2 KO MEFs and CLS fibroblasts exhibit a
significantly higher number of cH2AX foci per cell with longer
periods of AD treatment, indicating deficiencies in DNA repair in
RSK2-deficient cells. These findings demonstrate that both
RSK2- and Atm-deficient cells display similar functional defects,
presumably meditated by their common downstream target p53.
Thus our study suggests that RSK2 plays an important role in the
Atm/p53-dependent DNA damage pathway and DNA repair.
RSK2 does not contain a classic nuclear localization signal
(NLS), and the mechanism by which it translocates to the nucleus
has not been investigated previously. In response to mitogen
treatment, RSK2 is slowly released from stress granules and
shuttles rapidly in and out of the nucleus [37]. Atm is
predominantly present within the nucleus of cultured human
cells, with a small fraction present in the cytoplasm [41]. Several
studies have suggested that the phosphorylation status of RSK is
important for its nuclear translocation [38]. Other studies have
also indicated that various binding partners regulate the subcel-
lular distribution of RSK [39–40]. Here, we found that cytosolic
RSK2 translocates to the nucleus when DNA damage occurs. As
Atm is predominantly expressed in the nucleus, transport of RSK2
to the nucleus enables the formation of a RSK2-Atm complex and
activates the Atm/p53-dependent DNA damage pathway in
response to DNA damage. Atm, Atr, and DNA-PKs are DNA
damage-sensing protein kinases that signal the presence of DNA
lesions, initiate cell cycle arrest, and DNA repair or apoptosis
through a series of phosphorylation events [27].
Impaired DNA damage response would promote apoptosis [44].
We also observed that RSK2 KO cells exhibited decreased cell
viability and elevated cell death under genotoxic stress compared to
RSK2 WT cells (Fig. 5 A and B). However, we did not observe
alternations of Bax expression in both RSK2 WT and KO cells.
The expression of Bax is regulated by p53 and will be elevated
under apoptotic signals [45]. We postulated that in our experiments,
the Adriamycin treatment (0.5 mM) in immortalized MEF cells was
able to induce p53 signaling to cell cycle arrest but not severe
enough to induce massive apoptosis. Therefore we found that p21
but not Bax was up-regulated during genotoxic stress.
In summary, our study has uncovered a novel role for RSK2 in
a DNA damage and repair pathway that maintains genomic
stability by regulating cell cycle progression and DNA repair. We
believe that the elucidation of this regulatory network has greatly
enhanced our understanding of the underlying causes of cognitive
dysfunction observed in CLS. In addition, our results confirm the
link between CLS, a neurological disorder caused by mutated
RSK2, and defects in the DNA damage response.
Materials and Methods
Animals
All C57BL/6 mice were maintained in accordance with the
institutional guidelines, and all protocols were approved through
the Institutional Animal Care and Use Committee (IACUC) of the
National Neuroscience Institute, Tan Tock Seng Hospital. The
mice were maintained in a pathogen-free facility and exposed to a
12 h light/dark cycle with food and water.
Cell culture and transfection
Low passage (p3–p5) mouse embryonic fibroblasts (MEFs) were
prepared as previously described [46]. MEFs were cultured in
DMEM supplemented with 10% FCS and penicillin/streptomycin
in an atmosphere of 5% CO2 at 37uC. Human CLS (GM09621)
and healthy fibroblast cells (GM03321) were purchased from
Coriell Cell Repositories. The RSK2 knockout MEFs were
provided by Dr. R. Strachan, Duke University [47]. The RSK2
DNA constructs (imaGenes, GmbH) and Atm DNA constructs (a
kind gift from Dr. XY. Wang, the National University of
Singapore) were transfected into NIH cells and MEFs using
lipofectamine (Invitrogen) according to manufacturer’s protocol.
Genotoxic stress and antibodies
DNA damage was generated by inducing genotoxic stress with
0.5 mM Adriamycin (doxorubicin) (CalBiochem, USA). Antibodies
against RSK2 (#SC-9986), Ser227 RSK2 (#SC12445), Thr577
RSK2 (#SC-16407), and actin (#SC-69879) were purchased from
Figure 7. RSK2 maintains genome stability in response to
genotoxic stress. RSK2 is phosphorylated at both Ser227 and Thr577
in response to DNA damage. Activated RSK2 translocates to the nucleus
and interacts with Atm, thus activating the Atm/p53-dependent DNA
damage pathway, as well as p53-controlled cellular events. RSK2 KO
relieves AD-induced cell cycle arrest at the G2/M check point and
subsequently inhibited the DNA repair process, as indicated by the
increased formation of cH2AX foci.
doi:10.1371/journal.pone.0074334.g007
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Santa Cruz; antibodies against p53 (#2524) and Ser15 p53
(#9284) were purchased from Cell Signaling; antibodies against
Bax (#554104), p21 (#556430), and TopBP1 (#611875) were
purchased from BD Biosciences; the antibody against Atm
(GTX70103) was purchased from GeneTex; and the antibody
against Ser1981 Atm (200-301-400) was purchased from Rockland
Immunochemicals.
Chromatin Fractionation
MEF cells were treated with Adriamycin (AD) and harvested at
specific time points. Chromatin fractionation was performed as
described previously [21]. In brief, cells were incubated with
Buffer A containing 10 mM HEPES, 10 mM KCl, 1.5 mM
MgCl2, 0.34 M Sucrose, 10% Glycerol, 1 mM DTT, and a
mixture of protease and phosphatase inhibitors for 5 min and then
lysed. Triton X-100 was added to a final concentration of 0.1%.
Lysed cells were incubated on ice for 4 min and then centrifuged
at 1300 rcf for 4 min at 4uC. The supernatant (S1) and pellet (P1)
fractions were collected. The S1 fraction was further centrifuged at
1600 rcf for 15 min at 4uC, and the supernatant (S2) was collected.
The P1 fraction was washed once with Buffer A and lysed for
30 min on ice with Buffer B, which contained 3 mM EDTA,
0.2 mM EGTA, and a mixture of protease and phosphatase
inhibitors. The lysed P1 fraction was centrifuged at 1700 rcf for
4 min at 4uC. The resulting pellet (P3) was washed once with
Buffer B and re-suspended in Laemmli buffer. The S2 (cytosolic
proteins) and P3 (chromatin associated proteins) fractions were
then analyzed by SDS-PAGE and western blot.
Immunoprecipitation and western blot
After drug treatment, cells were washed with PBS and lysed in
RIPA buffer containing phosphatase and protease inhibitors. The
protein concentration was determined by Bio-Rad assay. Equal
amounts of protein (15 mg) were separated by electrophoresis on
SDS–PAGE gels and then transferred onto nitrocellulose mem-
branes (Millipore), which were probed with primary and secondary
antibodies, and visualized using an ECL kit (GE Healthcare). For
immunoprecipitation, antibodies were added to the cell lysates and
incubated at 4uC overnight, followed by incubation with Protein A
plus G beads at 4uC for 4 hr. The immunoprecipitated proteins
were released from the beads by boiling in 26 sample buffer for
5 min and subsequently analyzed by western blot.
FACs analysis
After drug treatment, cells were trypsinized with 0.05% trypsin
and 0.5 mM EDTA (Gibco BRL) at 37uC for 2 min and collected
by centrifugation at 1000 rpm for 5 min. For cellular DNA
content analyses, cells were then washed once in PBS and
subsequently fixed in 70% ethanol at 220uC overnight. The
ethanol solution was then removed, and the cells were washed
once with PBS containing 5 mM EDTA. The cells were then re-
suspended in hypotonic Propidium Iodide (PI) buffer for 3 hr in
the dark at room temperature as described previously [48]. Counts
of PI-stained cells were immediately acquired using an LSRII flow
cytometer (Becton and Dickinson Biosciences) and analyzed using
WinMDI Version 2.9 software (The Scripps Research Institute, La
Jolla, CA, USA).
WST-1 assay
WST-1 assay kit (Roche, Switzerland) was used to test cell
viability. Both the RSK2 WT and KO MEFs were seeded equally
into 96-well plate. The cells were treated with AD (0.5 mM) for
time periods as indicated (2–24 h), followed by incubation with
WST-1 (1:10) for additional 2 h. The absorbance at a wavelength
of 450 nm was measured by the microplate reader (Tecan,
Austria).
TUNEL assay
The in situ cell death detection kit (Roche, Switzerland) was used
for detecting cell injury after AD treatment. Both the RSK2 WT
and KO MEFs were seeded on cover slips. After treatment of
Adriamycin for 24 h, the cells were fixed in 4% paraformaldehyde
for 1 h at room temperature. Following fixation, the cells were
rinsed with PBS and permeabilized with 0.1% Triton X-100 in
0.1% sodium citrate on ice for 2 min. Then the cells were
incubated at 37uC with TUNEL reaction mixture for 1 h. The
TUNEL positive cells were visualized on a confocal microscope
(Olympus, FV-10).
Immunocytochemistry
After drug treatment, cells were fixed, permeabilized with
0.1% Triton X-100, and blocked with 2% BSA. Primary
antibodies against cH2AX (A300-081A, Bethyl Lab), Atm (SC-
7230, Santa Cruz), and RSK2 (SC-9986, Santa Cruz) were
added, followed by incubation with Alexa Fluor 555 Goat Anti-
Rabbit IgG (H+L) (Invitrogen, A21428), Alexa Fluor 488 Goat
Anti-Rabbit IgG (H+L) (Invitrogen, A11043), and Alexa Fluor
555 Donkey Anti-Mouse IgG (H+L) (Invitrogen, A31570)
secondary antibody. The slices were mounted with mounting
medium containing DAPI and visualized on a confocal
microscope (Olympus, FV-10).
Image acquisition, western blot quantification, and
statistical analysis
For each experiment, at least 3 independent replicates were
performed, and similar results were obtained. Representative
results from one experiment are shown. For quantification, all
western blots were scanned with a Molecular Dynamics scanning
densitometer. Statistical analysis was performed using ANOVA
and Student’s t test. All data are shown as the mean plus or minus
the standard deviation of the mean (mean 6 SD). A significant
difference was defined as *P,0.05, **P,0.01, and ***P,0.001
compared to the control.
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